The effective use of plerixafor as a real‐time rescue strategy for patients poorly mobilizing autologous CD34+ cells
Authors:
- 1 January 2012
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 27 (2) , 81-87
Abstract
Plerixafor enhances CD34+ cell mobilization, however, its optimal use is unknown. We hypothesized that plerixafor could “rescue” patients in the midst of mobilization when factors indicated a poor CD34+ yield. Of 295 consecutive autologous peripheral blood mobilization attempts at our center, 39 (13%) used plerixafor as rescue strategy due to a CD34+ cell concentration n = 30), low CD34+ cell yield from prior apheresis day (median 1.06 × 106 CD34+ cells/kg, n = 7), or other (n = 2). Patients received a median of one plerixafor dose (range: 1–4). Thirty‐four (87%) collected =2 × 10 6 CD34+ cells/kg and 26 (67%) collected =4 × 10 6 CD34+ cells/kg. Median collections for lymphoma (n = 24) and myeloma (n = 15) patients were 4.1 × 106 and 8.3 × 106 CD34/kg, respectively. A single dose of plerixafor was associated with an increase in the mean peripheral blood CD34+ concentration of 17.2 cells/μl (P < 0.001) and mean increased CD34+ cell yield following a single apheresis of 5.11 × 106/kg (P < 0.03). A real‐time rescue use of plerixafor is feasible and may allow targeted use of this agent. J. Clin. Apheresis, 2012.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experienceEuropean Journal of Haematology, 2011
- FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous TransplantationOncology, 2010
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensBlood, 2009
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experienceBone Marrow Transplantation, 2009
- High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and CytarabineJournal of Clinical Oncology, 2005
- Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple MyelomaJournal of Clinical Oncology, 2005
- Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemiaBlood, 2004
- Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilizationBone Marrow Transplantation, 1999
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995